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Expression of nucleoside-metabolizing enzymes in
myelodysplastic syndromes and modulation of response
to azacitidine
A Valencia1, E Masala1, A Rossi1, A Martino2, A Sanna1, F Buchi1, F Canzian2, D Cilloni3, V Gaidano3, MT Voso4, O Kosmider5,6,
M Fontenay5,6, A Gozzini1, A Bosi1 and V Santini1
The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail
to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely
to respond to AZA could impact the utility of this therapy. We determined the expression levels of genes involved in AZA
metabolism: UCK1, UCK2, DCK, hENT1, RRM1 and RRM2 using quantitative PCR in samples from 57 patients with MDS who received
AZA. Lower expression of UCK1 was seen in patients without a response to AZA (median 0.2 vs 0.49 for patients with response to
AZA, P¼ 0.07). This difference in UCK1 expression was not influenced by aberrant methylation of the UCK1 promoter. In addition,
the seven polymorphic loci found in the coding sequence were not associated with UCK1 gene expression nor AZA response.
Silencing of UCK1 by siRNA leads to blunted response to AZA in vitro. The univariate analysis revealed that patients expressing lower
than median levels of UCK1 had a shorter overall survival (P¼ 0.049). Our results suggest that expression level of UCK1 is correlated
with clinical outcome and may influence the clinical response to AZA treatment in patients with MDS.
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INTRODUCTION
The hypomethylating agent azacitidine (AZA) is the standard
therapy for the treatment of patients with higher-risk myelodys-
plastic syndromes (MDS) (International Prognostic Scoring System
(IPSS) intermediate-2 or high) and patients with acute myeloid
leukemia (AML) with 20–30% bone marrow (BM) blasts in Europe,
while in the United States it is approved for all French–American–
British (FAB) MDS subtypes. Although AZA is extensively used,
30–40% of patients fail to respond or relapse after treatment.1,2
There have been efforts to characterize biological and clinical
parameters predictive of response or resistance to AZA, and
although some have been identified, they have not yet been
validated to support clinical decisions.3–6 The concept that level of
DNA methylation may correlate with response to treatment has
been considered for some time, but there is not sufficient
evidence to fully confirm this hypothesis as few data are available.
For example, an initial study focused on CDKN2B methylation, but
this did not correlate with response.3 Similarly, phosphoinositide/
phospholipase C beta 1 was shown to be hypermethylated in
patients with MDS and reduction of methylation was correlated
with response to AZA.4,7 Moreover, Shen et al.8 showed that
reduced global methylation over time correlates with survival and
response to therapy in patients with MDS.
Several gene mutations that correlate with prognosis in patients
with MDS have been evaluated for their power to predict response
to AZA. For example, TET2 mutations correlated with response to
AZA but without impacting response duration or survival.9
Mutations in other genes involved in epigenetic regulation,
including DNMT3A, ASXL1, TET2 and IDH1/IDH2, may impact
response to AZA.10 It has also been shown that resistance to
AZA significantly correlated with the percentage of MDS or AML
cells expressing the BCL-2-like protein 10.5 Finally, clinical
parameters have been identified that independently predicted
lower response rates (previous low-dose cytosine arabinoside
(Ara-C), BM blasts415% and abnormal karyotype) and reduced
overall survival (OS) (performance status X2, intermediate- and
poor-risk cytogenetics, presence of circulating blasts and red
blood cell transfusion dependency with AZA) in patients with
higher-risk MDS.11
AZA is a nucleoside analog (NA) that mimics physiological
cytidine in terms of uptake into the cell and activation to
exert its pharmacological action.12,13 The concentrative
nucleoside transporter and equilibrative nucleoside transporter
proteins mediate the transport of NAs such as AZA across
membranes.14,15 Inside cells, AZA is activated by the enzyme
uridine-cytidine kinase (UCK).13,16 The majority (80–90%) of
activated AZA is incorporated into RNA resulting in mRNA and
protein metabolism disruption.17–19 A smaller fraction (10–20%)
of AZA is converted to decitabine (DAC) by ribonucleotide
reductase (RR) and incorporated into newly synthesized
DNA, depleting DNA methyltransferase 1 and leading to DNA
hypomethylation.15,17
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Many of the mechanisms of primary resistance to NAs are
related to alterations in components that impact their metabolism.20–24
Mutations in and/or expression levels of nucleoside-activating
or inactivating enzymes have been correlated with tumor
response or patient outcome with Ara-C.22–26 A recent work
indicated that increased cytidine deaminase (CDA; enzyme
inactivating NA) expression/activity in plasma of male MDS
patients contributes to decreased drug plasma half-life and
could account for worse outcomes with NA therapy.27
We hypothesized that alterations in AZA cellular uptake and
metabolism could be a mechanism for relapse or refractoriness to
treatment.
We studied the expression of genes encoding nucleoside
transporter proteins and enzymes involved in the metabolism of
AZA: UCK1 and UCK2, deoxycytidine kinase (DCK), human
equilibrative nucleoside transporter 1 (hENT1) and the two
subunits of the RR gene (RRM1 and RRM2) in samples from
primary MDS patients and correlated these data with response to
AZA and clinical outcomes.
PATIENTS AND METHODS
Patients
The study population included 57 patients diagnosed with MDS or AML
with 20–30% blasts between June 2006 and August 2012. MDS and AML
diagnosis was made in accordance with the World Health Organization
(WHO) criteria.28 Three chronic myelomonocytic leukemia cases were
diagnosed according to FAB morphological and cytogenetic criteria29 and
were included in the study. BM mononuclear cells were collected at
diagnosis or immediately before AZA treatment separated on Ficoll
Hypaque density gradient (Lympholyte-H; Cedarlane Labs, Hornby, ON,
Canada). Informed consent was provided in accordance with the
Declaration of Helsinki Principles and local Ethics Committee’s approval.
BM mononuclear cells from 10 healthy donors obtained after informed
consent were also separated as negative controls.
AZA was given subcutaneously following the schedule approved by the
US Food and Drug Administration and European Medicines Agency of
75 mg/m2 per day for 7 days every 28 days. Response was analyzed on an
intention-to-treat basis. Patients received at least two cycles of AZA and
underwent full BM and hematological evaluation to determine response
according to the International Working Group criteria for MDS30 and AML.31
Patients were considered responders when in complete remission (CR),
marrow CR (mCR), partial remission (PR) or hematological improvement
(HI) and non-responders when in stable disease (SD) or progressive disease
(PD). Characteristics of all patients are described in Table 1. Though the
IPSS score validation was stated for untreated patients with primary MDS,
patients who had received growth factors or short courses (p3 months) of
low-dose chemotherapy were included in the analysis.32 Herein, IPSS score
was recalculated before the onset of AZA therapy.
Expression analysis
Quantitative PCR (qPCR) was carried out with the ABI GeneAmp 5700
instrument and software (Applied Biosystems, Foster City, CA, USA).
Specific oligonucleotides and TaqMan probes were available from Applied
Biosystems (catalog no: UCK1: Hs01075618_m1; UCK2: Hs:00367072_m1,
DCK: Hs00176127_m1, hENT1: Hs01085706_m, RRM1: Hs01040698_m1,
RRM2: Hs01072069_g1). All qPCR experiments were normalized to the
housekeeping gene glyceraldehyde-2-phosphate dehydrogenase (GAPDH).
Each reaction was performed in duplicate.
The mean value of the replicates for each sample was calculated and
expressed as threshold cycle (CT) values. The amount of gene expression
was measured as the difference (DCT) between the CT value of the sample
for the target gene and the CT value of the sample for the GAPDH
endogenous control gene (DCT¼CT(Target)CT(GAPDH)). The results
were then expressed as 2 (DCt).
Methylation-specific PCR
One microgram of genomic DNA was converted with bisulfite before
amplification. After conversion, methylation of UCK1 was assessed by
methylation-specific PCR using specific primers (Supplementary Table S1).
DNA from mononuclear cells from healthy donors was used as a negative
control and methylated control DNA (CpGenome Universal Methylated
DNA; Intergen, Purchase, NY, USA) was used as positive control. The PCR
conditions were: hot start at 95 1C for 10 min followed by 40 cycles at 95 1C
for 30 s, 56 1C for 1 min, and 72 1C for 45 s, followed by a final extension at
72 1C for 10 min.
Sequencing analysis
The complete coding sequence of the UCK1 gene was sequenced by the
Sanger method. Five PCR amplicons were designed in order to encompass
all the exonic regions within the UCK1 gene, including at least 50 base pairs
at the intron/exon boundaries. Primers are listed in Supplementary Table S1.
The reaction products were loaded onto an ABI prism 3100 Genetic
analyzer (Applied Biosystems). Primary sequencing data were analyzed
using the Geneious software (Biomatters Ltd, Auckland, New Zealand) and
compared with the human UCK1 gene sequence and its complete coding
sequence (Gene ID: 83549, CCDS6944).
When enough DNA was available, standard PCR and sequencing of the
entire coding sequence (exons 3–11) of the TET2 gene were performed in
BM genomic DNA, as previously described.33
siRNA transfection
For UCK1 silencing, two siRNAs were used: SR313172C (siUCK1-1)
(AUAAUGAUUUGAUGCACAGGACUCT) and SR3131172B (siUCK1-2)
(GGUUUAAAGAUCCCUCUAGGUCACT) (OriGene Technologies, Inc., Rockville,
MD, USA). A designated non-targeting siRNA, scramble SR30005 (SCR),
provided a control for non-specific siRNA transfection effects on gene
expression. K562 cells were cultured at a density of 1 106 cells/ml in 6 ml
of RPMI 1640 medium. The TransIT-TKO transfection reagent was diluted in
medium free of antibiotics and the siRNAs in SR30005-Rnase-free siRNA
duplex re-suspension buffer, and then the two components were mixed.
After 30 min of incubation, K562 cells were cultured with the siRNAs,
the TKO transfectant reagent and the SCR. After 48 h of transfection, cells
Table 1. Patient characteristics
Characteristics (n, %)





















BM Blasts, n 54
o5% 9 (17)
X5% 45 (83)
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CMML,
chronic myelomonocytic leukemia; IPSS, International Prognostic Score
System; RA, refractory anemia; RAEB, RA with excess of blasts; RAEB-t, RA
with excess of blasts in transformation; RARS, RA with ringed sideroblasts;
RCMD, refractory cytopenia with multilineage dysplasia; WHO, World
Health Organization.
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were treated for further 24 h with AZA at the optimal concentration of 1 mM
as previously established in our laboratory.34 After treatment, cells were
washed, and RNA and proteins were extracted. Each experiment was
performed in duplicate. Effective UCK1 silencing was evaluated by qPCR
with the method described above.
Western blotting
The effective presence and downregulation of the UCK1 protein was
evaluated by western blotting. The protein extracts of the K562 cultures
were studied using the following antibodies: anti-UCK1 mouse monoclonal
antibody (1:1000, OriGene Technologies) and the antibody against
a-tubulin (1:1000; Sigma-Aldrich, St Louis, MO, USA) used to confirm
equal loading of extracts.
Annexin-V-binding assay
To quantify apoptosis, cells were washed twice with phosphate-buffered
saline, and the cell pellet was resuspended in 100 ml of Annexin-V-FLUOS
(HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffered sal-
ine solution with 2.5 mM CaCl2). Phycoerythrin-labeled Annexin-V (Roche
Diagnostics GmbH, Mannheim, Germany) and propidium iodide (PI) were
added, and cells were incubated for 15 min in the dark at room
temperature. After the addition of 400 ml of binding buffer and agitation,
flow cytometer analysis was performed using a FACSscan (Becton
Dickinson, Franklin Lakes, NJ, USA). Cells positively stained with Annexin-
V and PI-negative were considered apoptotic.
Statistical analysis
All descriptive statistics and tests (Mann–Whitney nonparametric U-test,
Kruskal–Wallis test, Chi-square test and Fisher’s exact test) were performed
using the statistical package SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA).
Regarding the polymorphic loci of UCK1, unconditional logistic regression
was used to assess genotype distributions between patients with or
without response to AZA, considering the homozygotes for the more
frequent allele as the reference class. Due to the small numbers of samples
available, heterozygous and homozygous subjects for the variant alleles
were grouped together. A P-value p0.05 was considered statistically
significant.
OS was defined as the time from initiation of AZA treatment to death
from any cause. Patients who remained alive were censored at the time of
last follow-up. Survival from time of MDS diagnosis was also evaluated in
patients with or without response to AZA. Time-to-event curves were
estimated by the Kaplan–Meier method and compared by stratified log
rank tests. Stratified Cox proportional hazards regression models were
used to estimate hazard ratios (HRs) and associated 95% confidence
intervals. The primary analysis of OS for patients with or without response
to AZA used the stratified Cox proportional hazards model without any
covariate adjustments to estimate the HR. All P-values reported are two sided.
RESULTS
Patient characteristics
This study included samples from 57 patients recruited from three
different centres in Italy (36/21 M/F with a median age at
diagnosis of 70 years (range, 37–86 years). At baseline, median
hemoglobin level, absolute neutrophil count and platelet
count were 8.9 g/dl (range, 6–14.1), 2 109 cells/l (range,
1 109–15 109) and 48 109/l (range, 3 109–267 109),
respectively. Median BM blast count was 13.2%. Cytogenetic risk
was good in 35 (64%), intermediate in 6 (11%) and poor in 14
(25%) patients. IPSS was intermediate-1 in 7 (13%), intermediate-2
in 33 (62%) and high in 13 (24%) patients. WHO diagnosis
included 4 (7%) cases of refractory anemia (RA), RA with ringed
sideroblasts or refractory cytopenia with multilineage dysplasia,
12 (22%) cases of RA with excess of blasts-1, 25 (46%) cases of
RA with excess of blasts-2 and 10 (18%) cases of RA with excess of
blasts in transformation/AML. Three patients (7%) were diagnosed
with chronic myelomonocytic leukemia according to the FAB
classification.
The median number of cycles of AZA received was 8 (range, 2–47).
Of the 57 patients, 23 (40%) achieved a response to AZA
(CR, PR, HI or mCR) and 34 (60%) did not (SD or PD) (Table 2).
Overall, median OS from initiation of AZA therapy was 27.2
months; patients who achieved CR/mCR, PR or HI had a median
OS of 54.1, 38 and 23.1 months, respectively, confirming that OS
was longer in patients with CR/PR/HI, compared with patients with
no response, as previously published.2 In fact, the median OS from
diagnosis in patients with or without a response to AZA was 72.3
and 35.1 months, respectively. When the scoring system designed
by Itzykson et al.11 for predicting OS after AZA was applied to our
MDS patients, 18% of them were included in the low-, 79% in the
intermediate- and 3% in the high-risk category.
Analysis of TET2 mutations
Eleven TET2 mutations were found in eight of 35 patients,
including three frameshift mutations (all inducing a premature
STOP codon), three nonsense and five missense mutations, all five
in the first conserved domain and one of them was found in
homozygosis. Three patients showed two different mutations
in the gene. Among patients with TET2 mutations, three patients
showed a response to AZA (CR, n¼ 1; PR, n¼ 1; and HI, n¼ 1)
while five patients did not (SD, n¼ 3; PD, n¼ 2) (P¼ 0.7).
Expression levels of enzymes involved in the metabolism of AZA in
MDS patients
Gene expression of the studied enzymes was heterogeneous
among MDS cases, and the level of mRNA expression was different
for the various genes (UCK1, median 0.25, Q1: 0.15–Q3: 0.55; UCK2,
median 0.45, Q1: 0.25–Q3: 0.76; DCK, median 5.2, Q1: 3.15–Q3:
10.9; hENT1, median 5.9, Q1: 2.7–Q3: 12.6; RRM1 median 1.3, Q1:
0.6–Q3: 2.6; and RRM2 median 9.2, Q1: 3.7–Q3: 20.1; Figure 1a).
We investigated the association between the expression of each
gene and the response to AZA treatment as well as other clinical
characteristics. Generally, the expression level of each gene was
not significantly different in patients with or without response to
AZA. However, lower expression of the UCK1 gene was shown in
patients without response to AZA (median 0.23 (Q1: 0.15–Q3: 0.40)
vs median 0.49 (Q1: 1.7–Q3: 9.3); P¼ 0.07) (Figure 1b). We also
evaluated the expression of UCK1 in the three different groups of
the AZA scoring system,11 observing no differences among them.
Mean UCK1 expression level in the low-risk group was 0.28±0.13,
in the intermediate 0.45±0.38 and in the high 0.15 (P¼ 0.22).
No correlation was found with age, sex, hemoglobin, absolute
neutrophil count, platelet count, WHO classification, cytogenetic
risk group, TET2 mutations, IPSS risk groups or BM blast
percentage for expression of UCK1, UCK2, DCK, hENT1, RMM1 or
RMM2 (data not shown).
Molecular alterations of UCK1 in MDS patients
In order to investigate the molecular events leading to differential
expression of UCK1, we measured the methylation status of the
CpG island at the UCK1 promoter. The CpG island was
unmethylated in all the samples analyzed and in healthy controls
(Figure 2a). To assess whether the difference in UCK1 expression
could be due to the presence of genetic variants, we sequenced
Table 2. Responses to azacitidine according IWG 2006 criteria
IWG 2006 responses n % Groups
Complete response 6 11 Responders (40%)
Partial response 6 11
Hematological improvement 8 15
Marrow complete response 3 5
Stable disease 23 38 Non-responders (60%)
Progressive disease 11 20
Abbreviation: IWG, Internatinal Working Group.
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the UCK1 coding sequence in a subset of 42 patients for which
genomic DNA was available. By this method, seven polymorphic
loci were identified. The position of the loci was compared with
resequencing data reported in the 1000 Genomes project
(http://www.1000genomes.org/). All seven loci corresponded to
known single-nucleotide polymorphism, three of which fell into intronic
sequences (rs3904960 in Intron 1; rs2296956 and rs189473964 in
Intron 3), two in regulatory sequences (rs7041225 in the 50
untranslated region; rs150900763 in the 30 untranslated region)
and two in the coding sequences of exon 2 (rs7867616, Glu29Gln)
and exon 6 (rs2296957, Ala180Ser) (Figure 2b). For the SNPs
rs189473964 and rs150900763, the variant allele was present in
only one subject, and these two SNPs were therefore excluded
from any further analysis. None of the remaining five variants were
shown to affect UCK1 expression levels (Figure 2c). Association of
genotypes with achievement of response to AZA was also
assessed, but none were found.
Silencing of UCK1 gene expression
To understand the effects of UCK1 on the sensitivity to AZA, we
carried out a knockdown experiment using two synthetic siRNAs
against the UCK1gene. K562 cells cultured in the presence of
two siRNAs for 48 h plus 24 h of exposure to AZA showed a
significant downregulation of the UCK1 mRNA compared with
control cultures with only one of the two siRNA tested (siUCK1-1
vs control, P¼ 0.046; siUCK1-1þAZA vs controlþAZA, P¼ 0.021;
Figure 3a). UCK1 protein expression was robustly diminished in
K562 cells exposed to siUCK1-1 (Figure 3b). When UCK1 was
downregulated, a reduction of AZA-induced apoptosis was
observed (siUCK1-1: Annexin V-positive cells 11%±0.34% vs
non-silenced control cultures: Annexin V-positive cells
31%±0.65%, P¼ 0.0015; Figure 3c). siUCK1-2 was not able to
silence the gene, and in that case, there was no variation in the
sensitivity to AZA with respect to control or mock transfected cells
(Supplementary Figure S1).
Prognostic impact of clinical characteristics and correlation with
UCK1 expression
To assess the variables predictive of OS from onset of AZA
treatment, we analyzed the baseline characteristics of sex,
age, BM blast percentage, IPSS risk score, cytogenetics
(within IPSS subgroups), score according to ‘AZA scoring
system’,11 TET2 mutations and the different genotypes found in
the UCK1 gene. Univariate analysis showed that OS was
significantly influenced only by IPSS risk score (P¼ 0.02) and
achievement of response to AZA (P¼ 0.001). Median OS by the
‘AZA scoring system’ was not reached in the low-risk group vs 44.7
months in the intermediate-risk group vs 14.9 months in the high-
risk group (P¼ 0.18). We also evaluated in the univariate analysis
the prognostic impact of the expression of UCK1, UCK2, DCK,
hENT1, RRM1 and RRM2. The median levels of gene expression
were used to divide cases with low (below median) or high
(above median) expression for each gene. We demonstrated that
patients with lower expression of UCK1 had shorter OS than
patients with higher expression of UCK1 (median OS values: 19
months vs 49 months; P¼ 0.041; Figure 4). Levels of UCK2, DCK,
hENT1, RRM1 and RRM2 expression did not significantly impact OS.
Multivariate analysis showed that the independent factors
influencing OS were achievement of response to AZA (HR, 0.23;
P¼ 0.0016) and higher expression of UCK1 (HR, 0.38; P¼ 0.049).
DISCUSSION
This study suggests that the expression of UCK1, involved in the
activation of AZA, may influence the clinical response to AZA
treatment in patients with MDS. The biological regulation of UCK1
expression was not due to methylation status of the UCK1
promoter nor to the presence of genetic polymorphisms in the
UCK1 sequence. Prolonged OS in this series of AZA-treated
patients with MDS was associated with higher expression of UCK1.
Hypomethylating agents AZA and DA have been shown to
induce overall responses in approximately 40–60% of patients
with MDS.1,2,35,36 However, only AZA has been shown to
significantly prolong OS in patients with IPSS higher-risk MDS.
In our cohort, we confirmed that response to AZA is correlated
with prolonged survival. There have been efforts to elucidate
factors predictive of response to AZA, in hopes of selecting
candidates most likely to respond to treatment. We applied the
‘AZA scoring system’11 to our cohort of MDS patients, and
although we could stratify them for OS, only a trend to longer
survival was observed for low scoring ones (9/57), the vast
majority belonging to intermediate scoring group. Both AZA and
DAC inhibit DNA methyltransferase activity and methylation of
new DNA strands. MDS is clinically the most responsive disease to
these agents, potentially due to its frequent aberrant










































































Figure 1. Expression of genes implicated in the metabolism of AZA. (a) Expression of UCK1, UCK2, DCK, hENT1, RRMI and RRM2 (relative to
GAPDH) in patients with MDS (n¼ 57) before AZA treatment. (b) Expression of UCK1 (relative to GAPDH) in patients without response to AZA
(SD or PD) vs patients with response to AZA (CR, PR, HI and mCR). In both plots, the thick middle line represents the median expression of the
different genes, and the top and bottom edges of the box represent the 75th and 25th percentiles, respectively. The outliers are also
represented by open and filled circles and asterisks.
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methylation.8,37 The correlation between the presence of
mutations in several epigenetic interfering genes (for example,
TET2, EZH2, ASXL1 and DNMT3) and response to AZA has been
shown but must be further confirmed to determine clinical
applicability.9,10,38 Only eight of the 35 MDS patients analyzed in
our study had mutated TET2. As expected, there was no
correlation with mutational status and OS, but we could not
observe higher rates of response to AZA in mutated cases, most
probably because of numerical limitations.
Although AZA and DAC have been shown to induce DNA
hypomethylation in vitro and in vivo,19 despite some reports,8
research has failed to elucidate the correlation between baseline
DNA hypermethylation and response to AZA or DAC. Therefore,
the identification of biological markers that permit the selection of
patients with MDS unlikely to respond to AZA therapy is of great
importance.
The cytosine NAs AZA and DAC are transported inside the cell
via specific proteins and then converted into active nucleotides to
induce DNA hypomethylation and cytotoxicity.39,40 An important
mechanism of resistance to NAs may be low levels of active
intracellular agent resulting from insufficient cellular uptake,
reduced levels of activating enzymes and increased degradation
of the agents. Therefore, we speculated that similar mechanisms
could account for resistance to AZA. The first ATP-dependent
phosphorylation, catalyzed by the enzyme UCK for AZA and DCK
for DAC,39,40 is a limiting step for AZA and DAC activation.
In particular, DCK deficiency has been reported as a major
mechanism of resistance to the NAs DAC, Ara-C and
gemcitabine.21,22,41,42 Recently, it has been reported that higher
plasma levels of CDA may account for worse outcome after NA
treatment in male MDS patients.27 In that study, CDA production
by the liver and its presence in plasma were evaluated, analyzing
its impact on DAC pharmacokinetics. We did not observe any
difference in AZA response rates between male and female
patients. On the other hand, there is still limited information
regarding the relationship between alterations in the components
of cellular AZA metabolism and the resistance seen in 30–40% of
AZA-treated patients with MDS.1,2 AZA incorporation into RNA
C(-) Blankmds25 mds54 mds50 mds49 mds198 mds236














UCK1 gene (chr9: 134,399,183-134,406,662)
EXON 6 PCR EXON 7 PCREXON 1 PCR




rs7041225 rs3904960 rs7867616 rs2296956 rs2296957





Figure 2. Molecular alterations of UCK1 in MDS patients. (a) Representative examples of methylation-specific PCR analysis of UCK1 in seven
MDS cases without response to AZA and six cases of MDS patients with response to AZA. C(þ ), DNA universally methylated; C( ), healthy
individual; blank, control without added DNA; U, unmethylated alleles; and M, methylated. (b) UCK1 gene locus and the sequenced regions.
Five PCR were designed to sequence the complete coding DNA sequence (Exon 1, Exon 2, Exon 3-5, Exon 6 and Exon 7) for all the isoforms of
the UCK1 protein. A total of seven common genetic variants, indicated by their reference number, were found to be polymorphic in at least
one subject. (c) UCK1 expression levels in different genotype groups. Gene expression values were compared with the genotypes of the
genetic variants identified. In the plots, the thick middle line represents the median expression of the different genes, and the top and bottom
edges of the box represent the 75th and 25th percentiles, respectively. The outliers are represented by asterisks.
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may enhance its clinical activity in MDS, as survival data suggest
superiority to DAC, which only undergoes DNA incorporation.13
We compared the expression of UCK1, UCK2, DCK, hENT1, RRM1
and RRM2 in MDS patients with or without clinical response to
AZA. Lower expression levels of UCK1 were shown in patients
resistant to AZA. In contrast to UCK1, expression levels of UCK2
were not significantly different in responsive vs non-responsive
patients. One may presume that both proteins phosphorylate AZA
to its nucleoside monophosphate, but our results suggest that
these two enzymes could act independently and do not seem to
have the same relevance in AZA metabolism. In MDS patients with
low expression of UCK1, we did not observe a compensatory
higher expression of UCK2. Consistently with our finding, it has
been demonstrated that the phosphorylation efficiency of the
enzymes UCK1 and UCK2 on the same substrate can be different.43
Levels of DCK, hENT1, RRM1 and RRM2 expression were not
associated with achievement of response to AZA. Additionally,
we also found that OS from onset of AZA treatment was
significantly shorter in patients with lower levels of UCK1
expression. The prognostic weight of UCK1 may reflect a
mechanism of action specific to AZA, which modulates protein
synthesis via RNA incorporation. RRM1 and RRM2 did not show
lower expression levels in patients without response to AZA in this
study. This could suggest that the step catalyzed by RRM1 and
RRM2, which converts AZA to DAC and leads to DNA
incorporation,18 is not discriminative for the clinical activity of
this agent.
Aberrant hypermethylation of UCK1 was not present in any
patient examined, including healthy controls. In addition,
the various polymorphisms found in the UCK1 sequence were
not related to its expression level nor with response to AZA
treatment, alternate to what has been demonstrated for DCK.44
We did not explore other possible mechanisms of gene expression
regulation, such as miRNA or splicing variants.45 However, UCK1
has several regulating miRNAs, (http://www.targetscan.org/) and
future studies are warranted, because miRNAs could be helpful
tools to modulate sensitivity to AZA. In fact, in order to explore





























































Figure 3. Silencing of the UCK1 gene. Effect of siUCK1-1 on the expression of the UCK1 gene (relative to GAPDH) was evaluated using
quantitative PCR (a) and western blotting analysis (b). Downregulation of the UCK1 mRNA by siUCK1-1 was observed in non-transfected
compared with mock transfected control cells, both not treated (*P¼ 0.046) and treated with AZA (**P¼ 0.021) (a). Mean of two different
experiments is shown. UCK1 protein expression was equally diminished in K562 cells exposed to siUCK1-1 (b). (c) Apoptosis (Annexin V-FITC
(fluorescein isothiocyanate) and PI staining) was measured in K562 cells cultured with SRC, TKO and siUCK1-1, without AZA and with 24-h
AZA. AZA induced an increase in Annexin V-positive cells, but apoptosis was blunted in K562 cells when siUCK1-1 was present and UCK1,
as well as UCK1 protein, were downexpressed (*P¼ 0.0015, siUCK1-1 transfected vs control culture).
Biological causes of resistance to azacitidine
A Valencia et al
626
Leukemia (2014) 621 – 628 & 2014 Macmillan Publishers Limited
functional assay, silencing UCK1 by siRNA. In the in vitro model, the
reduced expression of UCK1 in the leukemic cell line K562
decreased its otherwise significant AZA-induced apoptosis.
Although other variables may impact response in the clinical
setting, these results highlight the importance of UCK1 for AZA
activity.
Although we demonstrated that level of UCK1 expression is
correlated with outcome to AZA therapy, low expression of DCK,
which phosphorylates DAC, has been shown to impair sensitivity
in vitro to DAC.41 Although in hematological neoplasms treated
with NAs correlation of DCK levels with clinical outcome remains
controversial,46,47 we may envisage a future where selection of
patients with MDS to treat with AZA or DAC is possible on the
basis of their levels of UCK1 or DCK, in an attempt to decrease
primary resistance. Better definition of the relationship and
importance of enzyme expression to clinical response to AZA or
DAC in patients with MDS may help to elucidate their specific
mechanism of action and further optimize therapy.
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